Tag: Cancer Drugs

Startups Are Using AI to Predict Responses to Cancer Drugs
World

Startups Are Using AI to Predict Responses to Cancer Drugs

Dec. 28, 2023 12:01 pm ET|WSJ ProBiomedical startups are using artificial intelligence to predict the response patients will have to cancer treatments, aiming to increase the success of drugs in clinical trials and tailor therapies to individuals.As data accumulate from clinical trials and fields such as gene and protein research, AI is helping scientists sift through large volumes of information to uncover signatures that correlate with response—or resistance—to treatment. Startups are using it to predict which drugs are likely to work in clinical studies and create tests to help doctors choose treatments.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
A Tale of Two Pharmas: Can Obesity Firms Continue Their Outperformance in 2024?
Money

A Tale of Two Pharmas: Can Obesity Firms Continue Their Outperformance in 2024?

In pharma, you can take a larger slice of the healthcare pie than your peers, but you are still constrained by the size of the pie. No matter how good your cancer or diabetes drug is, healthcare systems will still have to keep paying for heart disease and rheumatoid arthritis treatments too.That, in a nutshell, is why the divergence of obesity-diabetes companies from the rest of the industry in recent years can’t go on forever. In 2023, Eli Lilly and Novo Nordisk have risen more than 50% each, to become the two largest pharma companies by market capitalization, with their combined value now hovering around $1 trillion. By comparison, the rest of the industry badly underperformed the market, with the NYSE Arca Pharmaceutical Index rising a measly 4% compared with 24% for the S&P 500.  ...
Bristol-Myers Squibb to Buy RayzeBio for $4.1 Billion
World

Bristol-Myers Squibb to Buy RayzeBio for $4.1 Billion

Updated Dec. 26, 2023 12:33 pm ETDrug company Bristol-Myers Squibb struck a $4.1 billion deal to buy RayzeBio, in a bet on a re-emerging cancer drug technology. RayzeBio develops radiopharmaceutical drugs, which use targeted forms of radiation that are delivered directly to cancer cells. Earlier products using the technology struggled commercially, but further research led to another wave of promising therapies that can attack tumors while limiting damage to surrounding healthy cells. Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Bristol-Myers Squibb to Buy RayzeBio for $4.1 Billion
World

Bristol-Myers Squibb to Buy RayzeBio for $4.1 Billion

Updated Dec. 26, 2023 12:19 pm ETDrug company Bristol-Myers Squibb struck a $4.1 billion deal to buy RayzeBio, in a bet on a re-emerging cancer drug technology. RayzeBio develops radiopharmaceutical drugs, which use targeted forms of radiation that are delivered directly to cancer cells. Earlier products using the technology struggled commercially, but further research led to another wave of promising therapies that can attack tumors while limiting damage to surrounding healthy cells. Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Health Care Roundup: Market Talk
World

Health Care Roundup: Market Talk

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.0902 GMT – Merck’s failure to reach key goals in late-stage clinical trials for its multiple sclerosis drug, evobrutinib, spells an end to its development and shifts the German pharmaceutical company’s focus to cancer drug xevinapant, Citi analysts say in a note. A potential treatment for late-stage head and neck cancer, xevinapant is in phase-3 clinical trials and might be “practice-changing” if it hits the market, say the analysts. They forecast sales of more than EUR1.4 billion, which is 25% ahead of consensus, saying that it is years ahead of competitors. “While evobrutinib’s failure is an obvious setback, we had previously argued the risk-reward was ...
AbbVie to Buy Cancer Biotech ImmunoGen for More Than $10 Billion
World

AbbVie to Buy Cancer Biotech ImmunoGen for More Than $10 Billion

Updated Nov. 30, 2023 10:37 am ETDrug company AbbVie has agreed to buy biotech ImmunoGen for $10.1 billion in a fresh bet on one of the most promising new technologies for attacking cancer.ImmunoGen develops cancer drugs called antibody-drug conjugates, or ADCs, which work like guided missiles delivering a toxic agent directly to tumors. The technology is among the hottest areas in the pharmaceutical industry. Recent advancements have spread its use to common kinds of cancer such as breast, spawning other multibillion deals.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Health Care Roundup: Market Talk
World

Health Care Roundup: Market Talk

Updated Nov. 14, 2023 5:07 pm ETThe latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.1155 ET – Canopy Growth has been blowing through far less cash after exiting its BioSteel business, but John Zamparo of CIBC says debt still weighs heavily on the cannabis company. In a report, the analyst says even by approaching positive Ebitda territory early next year, the improvement doesn’t address Canopy’s large and growing debt load. “Even if Canopy manages a 5% Ebitda margin, that still implies an annual free cash flow loss of more than $75 million because of interest charges,” he says. Instead, Zamparo thinks that only an equity issuance over the next few years can help solve the issue, “and recent examples of thi...
Bayer Pulling Lymphoma Drug Aliqopa From U.S.
World

Bayer Pulling Lymphoma Drug Aliqopa From U.S.

Nov. 13, 2023 10:35 am ETGerman drugs-to-crops giant Bayer is pulling Aliqopa from the U.S. after a confirmatory trial of the lymphoma drug missed its primary endpoint.Bayer on Monday said it will work with the U.S. Food and Drug Administration on a voluntary withdrawal of Aliqopa, which won accelerated approval from the agency in 2017 for adults with relapsed follicular lymphoma who have received at least two prior systemic therapies.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Wuxi Biologics Unit’s Hong Kong IPO Closes Order Book a Day Early, Sources Say
World

Wuxi Biologics Unit’s Hong Kong IPO Closes Order Book a Day Early, Sources Say

A unit of Chinese contract drugmaker Wuxi Biologics closed its order book a day early for its initial public offering and is likely to price the deal at the top of its marketed range, people familiar with the matter said, a rare instance of hot demand in a choppy year for listings in Hong Kong.Wuxi XDC Cayman is set to raise the equivalent of about US$470 million if it prices the IPO at the top end of its marketed price range, at 20.60 Hong Kong dollars (US$2.64) a share, the people said. The Wuxi, China-based company does research, development and manufacturing with a focus on antibody-drug conjugate, a type of medicine for cancer treatment.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
How Biden’s Inflation Reduction Act Killed a Cancer Study
Health

How Biden’s Inflation Reduction Act Killed a Cancer Study

President Biden has set an ambitious and laudable goal of reducing cancer mortality by half within 25 years, yet the Inflation Reduction Act (IRA) is working at cross purposes with that goal. See Seagen Inc. CEO David Epstein’s statement last week that the biotech company plans to scrap a new cancer drug study because of the law. The Food and Drug Administration approved Seagen’s antibody drug-conjugate Padcev in 2019 to treat locally advanced or metastatic bladder cancer that doesn’t respond to other therapies. Padcev uses an antibody that binds to specific proteins on cancer cells and directly delivers a payload of chemotherapy, which minimizes collateral damage to healthy non-cancerous cells.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1c...